In a study focusing on MAGE-A3 antibody immunotherapy, a comparative analysis of tissue microarray data from 22 melanoma patients who responded to immunotherapy and 34 who progressed showed significantly higher GZMK expression levels in the responders (P < 0.05) (Fig. 7A). Here, GZMK is linked to melanoma.